Integrative analyses of neuroimaging, clinical, and multi-omics data identified meaningful Alzheimer's disease progression **Subtypes**
Qiyuan An, ¹, Mengliang Zhang, ², Xinyue Hu, ³, Chang Su, ⁴, Yingying Zhu, ⁵

Qiyuan An, ', Mengliang Zhang, ', Xinyue Hu, ', Chang Su, ', Yingying Zhu, '
| Department of Computer Science and Engineering, University of Texas at Arlington [2] Department of Health Serv
| Administration and Policy, Tem

Abstract:

 $[1]$ Department of Computer Science and Engineering, Onversity of Texas at Arlington $[2]$ Department of Health Services
Administration and Policy, Temple University
stract:
heimer's Disease (AD) is a common neurodegener Administration and Policy, Temple Gilversity
Common neurodegenerative d
Lerstand differences between c
Ce in MRI ROI volumes among sub)
5.25
5.27 manifestations. To better understand differences between diverse manifestations, we
investigate from the difference in MRI ROI volumes among subtypes to their related
different gene pathways. In this study, we identify thr investigate from the difference in MRI ROI volumes among subtypes to their related
different gene pathways. In this study, we identify three subtypes of AD development
with fast, moderate, and slow progression rates from t different gene pathways. In this study, we identify three subtypes of AD developmen
with fast, moderate, and slow progression rates from the MRI ROI volume biomarker
the ADNI cohort. We further find differentially expresse with fast, moderate, and slow progression rates from the MRI ROI volume biomarkers
the ADNI cohort. We further find differentially expressed proteins in CSF fluids among
these AD patients and related significantly differen Whe ADNI cohort. We further find differentially expressed proteins in CSF fluids among
these AD patients and related significantly different genetic pathways. A total of 159
patients' data are included for analysis. We ide these AD patients and related significantly different genetic pathways. A total of 159
patients' data are included for analysis. We identify three distinct subtypes from the
hierarchical clustering on MRI ROI volume biomar matients' data are included for analysis. We identify three distinct subtypes from the
hierarchical clustering on MRI ROI volume biomarkers. Subtype 1, characterized as fa
progression, consists of 34 patients (21.9%). Subt patients of alternative on MRI ROI volume biomarkers. Subtype 1, characterized as fa
progression, consists of 34 patients (21.9%). Subtype 2, as moderate progression,
comprises 77 patients (49.6%). Subtype 3, as slow progr hologythesian, consists of 34 patients (21.9%). Subtype 2, as moderate progression,
comprises 77 patients (49.6%). Subtype 3, as slow progression, consists of 44 patients
(28.3%). These subtypes show significantly differen promprises 77 patients (49.6%). Subtype 3, as slow progression, consists of 44 paties (28.3%). These subtypes show significantly differences in cognitive test scores and corresponding genetic pathways. (28.3%). These subtypes show significantly differences in cognitive test scores and
corresponding genetic pathways.
Keywords:
1 Introduction (28.3%). Corresponding genetic pathways.

(28.3%). The Seywords:
 1 Introduction

Alzheimer's Disease (AD) is a complex and prevalent neurodegenerative disease, v

Keywords:

1 Introduction

Alzheimer's Disease (AD) is a con

etiology remains unclear to date keywords:
1
Alzheimer's
etiology rei
progressior \mathbf{r} introduction etiology remains unclear to date. It's heterogeneous in distinct clinical manifestations,
progression trajectories, volume biomarker readouts, and genetic pathways. Due to its
irreversible and age-related characters and la progression trajectories, volume biomarker readouts, and genetic pathways. Due to its
irreversible and age-related characters and lack of any cure, early diagnosis and
intervention of AD deterioration play an significant r progressible and age-related characters and lack of any cure, early diagnosis and
intervention of AD deterioration play an significant role in designing clinical treatment
strategies. One major challenge for AD prediction

intervention of AD deterioration play an significant role in designing clinical treatment
strategies. One major challenge for AD prediction and customized clinical treatment is
to identify the phenotypic heterogeneity with strategies. One major challenge for AD prediction and customized clinical treatment is
to identify the phenotypic heterogeneity within the AD population ¹.
Distinguishing subtypes in AD may lead to insights of different In identify the phenotypic heterogeneity within the AD population ¹.
Distinguishing subtypes in AD may lead to insights of different etiological mechanisms,
better the customized treatments, and interfere the development |
ס: 3
ג)[
ג) better the customized treatments, and interfere the development of brain atrophy and
dementia. The motivation of this study is to investigate into the progression patterns of
brain region volume biomarkers among different dementia. The motivation of this study is to investigate into the progression patterns of
brain region volume biomarkers among different participants in ADNI cohort, to reveal
the underlying atrophy development patterns am brain region volume biomarkers among different participants in ADNI cohort, to reveal the underlying atrophy development patterns among different subtypes. We cluster the participant features and identify three subtypes with distinct AD progression patterns in participant features and identify three subtributions and internal progression patterns in $\frac{1}{2}$ qxa5560@mavs.uta.edu
 $\frac{3}{2}$ xxh4034@mavs.uta.edu
 $\frac{4}{3}$ su.chang@temple.edu

5 yingying.zhu@uta.edu

mxz3935@mavs.uta.edu

xxh4034@mavs.uta.edu xxii+o5+@mavs.uta.edu
⁴ su.chang@temple.edu

 $\begin{array}{c} 1 & 2 & 3 \\ 2 & 3 & 4 \\ \end{array}$

su.chang@temple.edu 5 yingying.zhu@uta.edu

progression; and subtype 3, slow symptom progression.
Some previous attempts about neurodegenerative disease subtyping can be categorized
into the following categories: using neuroimaging biomarkes' readouts to identify
di Some previous attempts about neurodegenerative disea
into the following categories: using neuroimaging b
distinct patterns of atrophy regions^{ins}, using cognit
proteomics data^{vivii}. However, none of these works take
and cil C
Fa into the following categories: using neuroimaging biomarkes' readouts to identify
distinct patterns of atrophy regions¹¹¹¹¹, using cognitive test scores ^{ivv}, and using
proteomics data ^{vivii}. However, none of these wo Intertunational distinct patterns of atrophy regions¹¹¹¹¹, using cognitive test scores^{ivv}, and using
proteomics data^{vivit}. However, none of these works take advantage of all these features
and derive the underlying s

distinct patterns of atrophy regions^{im}, using cognitive test scores^{ive}, and using
proteomics data^{vivii}. However, none of these works take advantage of all these features
and derive the underlying significant genetic proteomics data^{svan}. However, none of these works take advantage of all these features
and derive the underlying significant genetic pathways.
To this end, we propose to identify subtypes of AD via the neuroimaging bioma and derive the underlying significant general pathways.
To this end, we propose to identify subtypes of AD vi
find differentially expressed proteins from Cerebrospil
and perform pathway enrichment analysis on omics
pathway ך
ו€
ו} This differentially expressed proteins from Cerebrospinal Fluid (CSF) proteomics data,
and perform pathway enrichment analysis on omics data to derive significant gene
pathways. We hope this study can provide insights to d Find differentially expressed parameters of the control proteins from particular party and perform pathway enrichment analysis on omics data to derive significant generathways. We hope this study can provide insights to di pathways. We hope this study can provide insights to discover individually customized
treatment for AD patients.
2 Experiments
2.1 Data Preprocessing pathways. We have the this study can patients.

The experiments

2.1 Data Preprocessing

Experiments

2 Experiments
2.1 Data Preprocessing
We adopt the ADNI TADPOLE challe $\frac{1}{2}$ We adopt the ADNI TADPOLE challenge dataset"" for our experiment. The TADPOLE
standard dataset includes the following biomarkers:
Main cognitive tests – neuropsychological tests administered by a clinical expert:
• CDR Sum standard dataset includes the following biomarkers:

Main cognitive tests – neuropsychological tests administered by a clinical expert:

• CDR Sum of Boxes

• ADAS 11

• ADAS 13

• MMSE

• RAVLT

• MOCA

Main cognitive tests interpretent in the property of the community of the community of the community of the ADAS 13

• ADAS 13

• MMSE

• RAVLT

• MOCA

-
- ADAS 11
• ADAS 13
• MMSE
• RAVLT
• MOCA
• Ecog
- ADAS 13
• MMSE
• RAVLT
• MOCA
• Ecog
	-
	-
	-
	-

• MMSE
• RAVLT
• MOCA
• Ecog
Is (Freesurfer) -• RAVLT
• MOCA
• Ecog
Is (Freesurfer)
• Volume • MOCA
• Ecog
Is (Freesurfer
• Volume
• Cortica • Ecog
Is (Freesurfer
• Volume
• Cortica
• Surface ls (Freesurfe
• Volur
• Cortia
• Surfa
• Alent the

-
-
-

 $\frac{1}{2}$ MARI ROIS CONTINUES ON A MARIN ROISE OF A MARIN STRUCTURE

• Cortical thicknesses

• Surface areas

We only adopt the MRI ROI volumes as inputs for subtyping,

to validate the subtyping results. The number of MRI ROI volu • Cortical t
• Surface a
y adopt the MRI
ate the subtypire
includes 1610 p • Surface areas
y adopt the MRI ROI volum
ate the subtyping results.
includes 1610 participants
AD participants, we filter of We only adopt the MRI ROI volumes as inputs for subtyping, while using cognitive tests
to validate the subtyping results. The number of MRI ROI volumes is 270. The TADPOLE
dataset includes 1610 participants, which consist)
(
(to validate the subtyping results. The number of MRI ROI volumes is 270. The TADPOLE
dataset includes 1610 participants, which consists of 342 AD, 417 CN, and 872 MCI. Out
of 342 AD participants, we filter out participant dataset includes 1610 participants, which consists of 342 AD, 417 CN, and 872 MCI. Out
of 342 AD participants, we filter out participants with less than 12 months longitudinal
data and result in 313 participants. After tha of 342 AD participants, we filter out participants with less than 12 months longitudinal
data and result in 313 participants. After that, we build each participant's speed feature
defined as $\frac{lastvisit-firstvisit}{timeinterval}$, representing th data and result in 313 participants. After that, we build each participant's speed feature
defined as $\frac{lastvisit-firstvisit}{timeinterval}$, representing the progression rates of different ROI
volumes. Then we filter the speed feature matrix in defined as $\frac{lastvisit-firstvisit}{timeinterval}$, representing the progression rates of different ROI
volumes. Then we filter the speed feature matrix in both the participants and the ROI
volume dimensions if the missing rate is greater than 0. defined as "
volumes. Then
volume dimer
volume dimer s ivisit $-$ j ir stvisit timeinterval
we filter the speed feature matrix in both the participants and the ROI
ions if the missing rate is greater than 0.7. Filtering speed features
ions if the missing rate is greater than 0.7. Filtering speed feat volume dimensions if the missing rate is greater than 0.7. Filtering speed features volume dimensions if the missing rate is greater than α . Filtering speed features
in the missing speed features is greater than α .

minmax normalization on the speed feature matrix.

2.2 Matrix Decomposition

We decompose the speed matrix via Truncated SVD with rank of 3 to derive

participants' features. The choice of Truncated SVD is for its native s **2.2 Matrix Decomposition**
We decompose the speed matrix via Truncate
participants' features. The choice of Truncated SVD
matrix as our speed feature matrix has many missir
of decomposition is via the sklearn library^{ix}. **2.2 Matrix Decomposition**
We decompose the speed matrix via Truncated SVD with rank of 3 to derive matricipants' features. The choice of Truncated SVD is for its native suitability for sparse
matrix as our speed feature matrix has many missing values. The actual implementation
of decomposition is via the sklearn library matrix as our speed feature matrix has many missing values. The actual implementation
of decomposition is via the sklearn library^{ix}.
2.3 Clustering
Then we cluster decomposed participants' features via the hierarchical

matrix as our speed feature matrix has may missing smaller interacting the decomposition is via the sklearn library^{ix}.

2.3 Clustering

Then we cluster decomposed participants' features via the hierarchical clustering to ร
ว
:6
:6 Then we cluster decomposed participants' features via the hierarchical clustering to avoid the biased/wrong prior hypothesis of number of subtypes. Our clustering results
in 3 phenotypes (number of participants) that correspond to fast progression (34),
moderate progression (44), and mild progression (77). in 3 phenotypes (number of participants) that correspond to fast progression (34),
moderate progression (44), and mild progression (77). We validate the subtyping results
on cognitive test scores shown in Fig 1. moderate progression (44), and mild progression (77). We validate the subtyping results on cognitive test scores shown in Fig 1. on cognitive test scores shown in Fig 1. on cognitive test scores shown in Fig 1.

 Figure 1. Cognitive test scores in 3 subtypes. Red: subtype 1, yellow: subtype 2, gray: subtype 3.

Each strip in Fig 1 represents the longitudinal trend on one cognitive test of one subtype.

between the solid line is the standard error. The clear separability of cognitive scores
justifies the legitimacy of our method on different progression trends.
2.4 Significance test on ROI volumes
We perform the Kruskal justifies the legitimacy of our method on different progression trends.

2.4 Significance test on ROI volumes

We perform the Kruskal-Wallis test among ROI volumes under different subtypes and

below Table 1 and Fig. 2 sho 2.4 Significance test on ROI volumes
We perform the Kruskal-Wallis test among ROI volumes under diffe
below Table 1 and Fig. 2 show significant ROI volumes. The choice
rather than the ANOVA test is because distributions of 2.4 Significance test on ROI volumes
We perform the Kruskal-Wallis test among ROI volumes under different subtypes and We perform the Kruskal-Wallis below Table 1 and Fig. 2 show significant ROI volumes. The choice of Kruskal-Wallis rather than the ANOVA test is because distributions of ROI volumes are not normal distribution.

ELDNAME

Vo rather than the ANOVA test is because distributions of ROI volumes are not normal distribution.

Table 1: Significant ROI volumes and p-values Table 1: Significant ROI volumes and p-values

12 proteins from subtyping

Insortium CSF Proteomics MRM data

s between each subtype and normarkers

participants between 3 subtypes a

has 13, and subtype 3 has 20 response 2.5 Find significant proteins from subtyping significantly different proteins between each subtype and normal control (CN) group.
The intersected number of participants between 3 subtypes and the CSFMRM are
subtype 1 has 10, subtype 2 has 13, and subtype 3 has 20 res The intersected number of participants between 3 subtypes and the CSFMRM are subtype 1 has 10, subtype 2 has 13, and subtype 3 has 20 respectively. While the number of CN participants between the TADPOLE dataset and CSF pr

subtype 1 has 10, subtype 2 has 13, and subtype 3 has 20 respectively. While the
number of CN participants between the TADPOLE dataset and CSF proteomics is 86.
We first build a contrast matrix between each pair of subtype number of CN participants between the TADPOLE dataset and CSF proteomics is 86.
We first build a contrast matrix between each pair of subtype and CN conditioned on
age, gender, and year of education factors to eliminate th We first build a contrast matrix between each pair of subtype and CN conditioned
age, gender, and year of education factors to eliminate the bias introduced by tl
factors. Then we fit a linear model for each pair of subtyp t
s
i age, gender, and year of education factors to eliminate the bias introduced by these
factors. Then we fit a linear model for each pair of subtype and CN and find significant
proteins by thresholding $|\log FC| > 0.2$ and Padj < Factors. Then we fit a linear model for each pair of subtype and CN and find significant
proteins by thresholding $|logFC|> 0.2$ and Padj < 0.05 from the empirical Bayes's
statistical tests. The p-value (Padj) is corrected b proteins by thresholding $|logFC| > 0.2$ and Padj < 0.05 from the empirical Bayes's
statistical tests. The p-value (Padj) is corrected by FDR. The actual implementation is via
limma library in R. The resulted significant prote statistical tests. The p-value (Padj) is corrected by FDR. The actual implementation is via
limma library in R. The resulted significant proteins are in Table 2.

**CADA
2: Sigi
ignifica**
ignifican

Ind significant pathways from proteins
the significant proteins between each pair of subtype and
the control of the CN. $\frac{1}{2}$ 2.6 Find significant pathways from proteins A after we obtain the significant proteins between each pair of subtype and CN, we adopte

g: profiler^x to perform pathway enrichment analysis and determine statistically enriched gene pathways. We correct p-value of 0.05 threshold with the Benjamini-Hochberg FDR. The gene data sources are GO molecular function, GO cellular component, GO biological process, KEGG, and Reactome. Then we filter output significant pathways by limiting process, KEGG, and Reactome. Then we filter output significant pathways by limiting term size between 5 and 350. The resulted pathways between each subtype and CN are listed in Fig 3.

Figure 3. Genetic pathways in 3 subtypes. Red: subtype 1, yellow: subtype 2, gray: subtype 3.

References References

 $\ddot{}$ ¹ Satone et al., "Learning the Progression and Clinical Subtypes of Alzheimer's Disease from Longitudinal
Clinical Data."

Clinical Data.
^{||} Francisc rice| ii Ferreira et al., "Distinct Subtypes of Alzheimer's Disease Based on Patterns of Brain Atrophy:
Legaltudies Enclisated and Clinical Auglications «

Longitudinal Trajectories and Clinical Applications." iii Goyal et al., "Characterizing Heterogeneity in the Progression of Alzheimer's Disease Using Longitudinal Clinical and Neuroimaging Biomarkers"; Su et al., "Comprehensively Modeling Heterogeneous Symptom Progression for Parkinson's Disease Subtyping."

 $^{\circ}$ Faghri et al., "Identification and Prediction of Parkinson's Disease Subtypes and Progression Using .

widdinite Learning in Two Conorts.
" Satone et al., "Predicting Alzheim Satone et al., "Predicting Alzheimer's Disease Progression Trajectory and Clinical Subtypes Using Machine Learning"; Brendel et al., "Comprehensive Subtyping of Parkinson's Disease Patients with

Similarity Fusion: A Case Study with BioFIND Data." vi Budgeon et al., "Constructing Longitudinal Disease Progression Curves Using Sparse, Short-Term Individual Data with an Application to Alzheimer's Disease"; Faghri et al., "Identification and Prediction of
Parkinson's Disease Subtypes and Progression Using Machine Learning in Two Cohorts." Parkinson's Disease Subtypes and Progression Using Machine Learning in Two Cohorts."

vii ins et al., "Pathophysiological Subtypes of Alzheimer's Disease Based on Cerebrospinal Fluid.
Past semise "

Proteomics.
^{Vill} Martin - - - - vii Marinescu et al., "Tadpole Challenge: Prediction of Longitudinal Evolution in Alzheimer's Disease."
" Redissesse at al. "Saliit Leaver Meebine Leaving in Rythea."

 \overline{a} Pedregosa et al., "Scikit-Learn: Machine Learning in Python."

 $^\circ$ Reimand et al., "Pathway Enrichment Analysis and Visualization of Omics Data Using g: Profiler, GSEA, .
C tassens and Freishmant Law ... Cytoscape and EnrichmentMap."

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.11.01.22281820;](https://doi.org/10.1101/2022.11.01.22281820) this version posted November 2, 2022. The copyright holder for this preprint

Subtype 1

Subtype 2

Subtype 3

